SynthesisBritish journal of cancer2011
Markers for the non-invasive diagnosis of mesothelioma: a systematic review.
Synthesis in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- Diagnostic accuracy of MOC-31 for malignant effusions: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.BMJ open · 2014Pooled it
- A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer.PloS one · 2014Pooled it
- Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Pooled it
- Article
- The rare occurrence of unifocal peritoneal mesothelioma: a case report, literature review, and future directions.Journal of gastrointestinal oncology · 2024Article
- Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology.Cancer medicine · 2023Article
- Ultrasound multiple scattering with microbubbles can differentiate between tumor and healthy tissue in vivo.Physics in medicine and biology · 2019Article
- Capture of mesothelioma cells with 'universal' CTC-chip.Oncology letters · 2018Article
- Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.Oncotarget · 2017Review
- CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.Respiratory research · 2017Review
- Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Scientific reports · 2016Article
- MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.Journal of thoracic disease · 2015Review
- Differential diagnosis of pleural mesothelioma using Logic Learning Machine.BMC bioinformatics · 2015Article
- Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.Molecular & cellular proteomics : MCP · 2014Article
- Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.BioMed research international · 2014Article
- Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.Journal of thoracic disease · 2013Review
- Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.Molecular and clinical oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous markers have been evaluated to facilitate the non-invasive diagnostic work-up of mesothelioma. The purpose of this study was to conduct a structured review of the diagnostic performance of non-invasive marker tests for the detection of mesothelioma in patients with suspected mesothelioma.
methodsStudies on the diagnostic accuracy of serum and cytological markers published till 31 December 2009, available in either PUBMED or Embase, to detect or exclude the presence of mesothelioma were extracted. Study quality was assessed with use of the Quadas criteria.
resultsIn total, 82 articles were included in this systemic review. Overall, quality of the incorporated studies to address our objective was poor. The most frequently studied immunohistochemical markers for cytological analysis were EMA, Ber-Ep4, CEA, and calretinin. The most frequently investigated serum marker was soluble mesothelin-related protein (SMRP). The markers CEA, Ber-EP4, and calretinin were most valuable in discriminating mesothelioma from other malignant diseases. Markers EMA and SMRP were most valuable in discriminating mesothelioma from non-malignant diseases. No marker performed well in discriminating between mesothelioma and all other diseases.
conclusionCurrently, there is only limited evidence to properly assess the value of non-invasive marker tests in the diagnosis of mesothelioma. Studies were of limited value to address our objective and results showed considerable unexplained study heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.